



Centre for
Public Health

Merseyside Inter Agency Drug Misuse Database

January – March 2007

Warrington DAT

Quarter 4 2006/07

**Esther Shepherd, Martin Chandler,
Jim McVeigh**

DRAFT REPORT

The final version will be available on the IAD website

www.cph.org.uk/iad

Acknowledgements:

The Authors would like to thank the following for their valuable contributions to the production of this report: Paul Duffy, Adam Marr, Simon Russell and Claire Shaw.

We would also like to thank the data providers for their efforts in assisting and maintaining the monitoring process

Contacts:

Martin Chandler
IAD Manager
Centre for Public Health
Faculty of Health & Applied Social Sciences
Liverpool John Moores University
Castle House
North Street
L3 2AY

(0151) 231 4531

m.chandler@ljmu.ac.uk

Esther Shepherd

IAD Researcher

(0151) 231 4521

e.shepherd@ljmu.ac.uk

www.cph.org.uk/iad

Contents

	<u>Page</u>
Introduction	1
Arrest Referral	3
Table 1: Individuals assessed, by Gender and Age Group	
Table 2: Year to Date, by Gender and Age Group	
Table 3: Reported Main Drug(s) of Use, by Frequency of Use	
Probation	5
Table 4: Probation clients by Gender and Age Group	
Table 5: Year to Date, by Gender and Age Group	
Table 6: Reported Main Drug(s) of Use, by Frequency of Use	
Syringe Exchange Services	7
Agency	
Table 7: Individuals by Gender	
Table 8: Individuals by Gender: Steroid Users Omitted	
Table 9: Individuals by Age Group	
Table 10: Individuals by Age Group: Steroid Users Omitted	
Table 11: Gender by Age Group of Individuals	
Table 12: Gender by Age Group: Steroid Users Omitted	
Table 13: Year to Date, by Gender & Age Group	
Table 14: Year to Date, by Gender & Age Group: Steroid Users Omitted	
Table 15: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender	
Table 16: Main Drug of Use, for New Agency Syringe Exchange Clients, by Age Group	
Pharmacy	12
Table 17: Individuals by Gender	
Table 18: Individuals by Age Group	
Table 19: Year to Date, by Gender & Age Group	
Combined	13
Table 20: Individuals in Syringe Exchange, by Gender	
Table 21: Individuals in Syringe Exchange, by Gender: Steroid Users omitted	
Table 22: Individuals in Syringe Exchange, by Age Group	
Table 23: Individuals in Syringe Exchange, by Age Group: Steroid Users omitted	
Table 24: Year to Date, by Gender & Age Group	
Table 25: Total Syringes Provided	

National Drug Treatment Monitoring System (NDTMS) 15

Table 26: Individuals in Contact with Treatment Services, by Gender

Table 27: Year to Date, by Gender

Table 28: Individuals in Contact with Treatment Services, by Age Group

Table 29: Year to Date, by Age Group

Table 30: Ethnicity of Individuals in Contact with Treatment Services

Table 31: Individuals in contact with Treatment Services, by Main Drug of Use

Combined Datasets 18

Table 32: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Table 33: Year to Date, by Gender & Age Group

Cross Matched Datasets 19

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets

Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

PLEASE NOTE: The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report. However, Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in

order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)**Quarter 4 (2006/07)****Introduction**

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	11	91.7
Female	1	8.3
Age Group		
Under 18	0	0
18-19	0	0
20-24	4	33.3
25-29	3	25.0
30-34	1	8.3
35-39	2	16.7
40-44	2	16.7
45+	0	0
Total	12	100

Table 2: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0	0	0	0	0
18-19	4	7.4	1	12.5	5	8.1
20-24	10	18.5	0	0	10	16.1
25-29	10	18.5	3	37.5	13	21.0
30-34	15	27.8	3	37.5	18	29.0
35-39	7	13.0	0	0	7	11.3
40-44	6	11.1	0	0	6	9.7
45+	2	3.7	1	12.5	3	4.8
Total	54	100	8	100	62	100

Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly
Amphetamines	0	0
Benzodiazepines	3	0
Cannabis	2	0
Crack	3	4
Cocaine	2	2
Ecstasy	0	1
Heroin	7	1
Methadone	2	0

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where “Main drug” is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the “Main Drug”. However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

PROBATION

Quarter 4 (2006/07)

Introduction

Data is provided by Cheshire Probation Services. Data relates to individuals reported through OASys with a reported substance use problem. Individuals who are on ASROs or similar treatment orders are reported to NDTMS.

NOTE: Probation figures are based on DAT of Residence, NOT DAT of contact as with other datasets.

Table 4: Probation Clients by Gender and Age Group

Gender	n	%
Male	38	86.4
Female	6	13.6
Age Group		
Under 18	0	0
18-19	4	9.1
20-24	14	31.8
25-29	8	18.2
30-34	11	25.0
35-39	4	9.1
40-44	2	4.5
45+	1	2.3
Total	44	100

Table 5: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0	0	0	0	0
18-19	21	10.7	1	3.3	22	9.7
20-24	49	25.0	2	6.7	51	22.6
25-29	35	17.9	7	23.3	42	18.6
30-34	37	18.9	10	33.3	47	20.8
35-39	18	9.2	4	13.3	22	9.7
40-44	21	10.7	4	13.3	25	11.1
45+	15	7.7	2	6.7	17	7.5
Total	196	100	30	100	226	100

Table 6: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly
Benzodiazepines	1	0
Cannabis	4	6
Crack	1	1
Heroin	2	0
Methadone	2	0

NB: Table 6 shows the number of people reporting daily or weekly use of specific drugs. This is to reflect reporting of polydrug use through Probation data. No totals are given as clients can report daily or weekly use of more than one drug and may therefore be double counted between drugs.

SYRINGE EXCHANGE SERVICES

Quarter 4 (2006/07)

Introduction

Data are collected directly from syringe exchange providers. Analysis of syringe exchange data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

AGENCY SYRINGE EXCHANGE

Please Note: Agency SES data for March 07 was not available in time for this report.

Table 7: Individuals by Gender

New Clients	n	%
Male	12	100
Female	0	0
<i>Total</i>	<i>12</i>	<i>100</i>
All Clients		
Male	132	95.0
Female	7	5.0
<i>Total</i>	<i>139</i>	<i>100</i>

Table 8: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	4	100
Female	0	0
<i>Total</i>	<i>4</i>	<i>100</i>
All Clients		
Male	43	86.0
Female	7	14.0
<i>Total</i>	<i>50</i>	<i>100</i>

Table 9: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	0	0
18-19	1	8.3	4	2.9
20-24	4	33.3	25	18.0
25-29	3	25.0	23	16.5
30-34	0	0	35	25.2
35-39	2	16.7	28	20.1
40-44	1	8.3	14	10.1
45+	1	8.3	10	7.2
Total	12	100	139	100

Table 10: Individuals by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	0	0
18-19	0	0	0	0
20-24	1	25.0	6	12.0
25-29	1	25.0	6	12.0
30-34	0	0	14	28.0
35-39	1	25.0	15	30.0
40-44	1	25.0	5	10.0
45+	0	0	4	8.0
Total	4	100	50	100

Table 11: Gender by Age Group of Individuals

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	0	0	0	0
18-19	4	3.0	0	0
20-24	23	17.4	2	28.6
25-29	23	17.4	0	0
30-34	33	25.0	2	28.6
35-39	26	19.7	2	28.6
40-44	13	9.8	1	14.3
45+	10	7.6	0	0
Total	132	100	7	100

Table 12: Gender by Age Group: Steroid Users Omitted

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	0	0	0	0
18-19	0	0	0	0
20-24	4	9.3	2	28.6
25-29	6	14.0	0	0
30-34	12	27.9	2	28.6
35-39	13	30.2	2	28.6
40-44	4	9.3	1	14.3
45+	4	9.3	0	0
Total	43	100	7	100

Table 13: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0	0	0	0	0
18-19	8	1.8	1	3.4	9	1.9
20-24	80	18.3	5	17.2	85	18.2
25-29	100	22.9	5	17.2	105	22.5
30-34	107	24.5	10	34.5	117	25.1
35-39	82	18.8	5	17.5	87	18.7
40-44	30	6.9	2	6.9	32	6.9
45+	30	6.9	1	3.4	31	6.7
Total	437	100	29	100	466	100

Table 14: Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0	0	0	0	0
18-19	0	0	1	3.4	1	0.5
20-24	13	8.4	5	17.2	18	9.8
25-29	18	11.6	5	17.2	23	12.5
30-34	54	34.8	10	34.5	64	34.8
35-39	42	27.1	5	17.2	47	25.5
40-44	16	10.3	2	6.9	18	9.8
45+	12	7.7	1	3.4	13	7.1
Total	155	100	29	100	184	100

Table 15: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Heroin	2	16.7	0	0
Steroids	8	66.7	0	0
Unknown	2	16.7	0	0
Total	12	100	0	0

Please Note: Due to changes in reporting methods we will now only report drug of use for new clients. Information on drug of use for all clients is available on request.

Table 16: Main Drug of Use for New Agency Syringe Exchange Clients, by Age Group

Age Group	Heroin		Steroids		Unknown	
	n	%	n	%	n	%
Under 18	0	0	0	0	0	0
18-19	0	0	1	100	0	0
20-24	0	0	3	75.0	1	25.0
25-29	0	0	2	66.7	1	33.3
30-34	0	0	0	0	0	0
35-39	1	50.0	1	50.0	0	0
40-44	1	100	0	0	0	0
45+	0	0	1	100	0	0
Total*	2	16.7	8	66.7	2	16.7

* % Totals are by Drug, not Age Group

PHARMACY SYRINGE EXCHANGE

Table 17: Individuals by Gender

New Clients	n	%
Male	90	90.0
Female	10	10.0
<i>Total</i>	<i>100</i>	<i>100</i>
All Clients		
Male	177	89.4
Female	21	10.6
<i>Total</i>	<i>198</i>	<i>100</i>

Table 18: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	0	0
18-19	7	7.0	10	5.1
20-24	18	18.0	36	18.2
25-29	22	22.0	42	21.2
30-34	20	20.0	43	21.7
35-39	20	20.0	38	19.2
40-44	9	9.0	17	8.6
45+	4	4.0	12	6.1
<i>Total</i>	<i>100</i>	<i>100</i>	<i>198</i>	<i>100</i>

Table 19: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female		n	%
	n	%	n	%		
Under 18	0	0	0	0	0	0
18-19	27	6.7	0	0	27	5.9
20-24	86	21.2	5	10.0	91	20.0
25-29	77	19.0	13	26.0	90	19.7
30-34	86	21.2	11	22.0	97	21.3
35-39	79	19.5	14	28.0	93	20.4
40-44	26	6.4	4	8.0	30	6.6
45+	25	6.2	3	6.0	28	6.1
<i>Total</i>	<i>406</i>	<i>100</i>	<i>50</i>	<i>100</i>	<i>456</i>	<i>100</i>

COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 20: Individuals in Syringe Exchange, by Gender

New Clients	n	%
Male	101	91.0
Female	10	9.0
<i>Total</i>	<i>111</i>	<i>100</i>
All Clients		
Male	297	91.7
Female	27	8.3
<i>Total</i>	<i>324</i>	<i>100</i>

Table 21: Individuals in Syringe Exchange, by Gender: Steroid Users Omitted

New Clients	n	%
Male	5	100
Female	0	0
<i>Total</i>	<i>5</i>	<i>100</i>
All Clients		
Male	208	88.5
Female	27	11.5
<i>Total</i>	<i>235</i>	<i>100</i>

Table 22: Individuals in Syringe Exchange, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	0	0
18-19	8	7.2	13	4.0
20-24	21	18.9	59	18.2
25-29	25	22.5	63	19.4
30-34	20	18.0	74	22.8
35-39	22	19.8	62	19.1
40-44	10	9.0	31	9.6
45+	5	4.5	22	6.8
<i>Total</i>	<i>111</i>	<i>100</i>	<i>324</i>	<i>100</i>

Table 23: Individuals in Syringe Exchange by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	0	0
18-19	0	0	9	3.8
20-24	1	20.0	40	17.0
25-29	1	20.0	46	19.6
30-34	0	0	53	22.6
35-39	2	40.0	49	20.9
40-44	1	20.0	22	9.4
45+	0	0	16	6.8
Total	5	100	235	100

Table 24: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0	0	0	0	0
18-19	33	4.2	1	1.4	34	4.0
20-24	157	19.9	9	12.7	166	19.3
25-29	165	20.9	16	22.5	181	21.0
30-34	179	22.7	17	23.9	196	22.8
35-39	147	18.6	18	25.4	165	19.2
40-44	54	6.8	6	8.5	60	7.0
45+	54	6.8	4	5.6	58	6.7
Total	789	100	71	100	860	100

Table 25: Total Syringes Provided

	This Quarter	Year to Date
Barrels	15,122	60,837
Needles	20,944	88,679

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

National Drug Treatment Monitoring System (NDTMS)

Quarter 4 (2006/07)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

Table 26: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	60	67.4
Female	29	32.6
<i>Total</i>	89	100
All Clients		
Male	706	75.5
Female	229	24.5
<i>Total</i>	935	100

Table 27: Year to Date, by Gender

New Clients	n	%
Male	253	76.7
Female	77	23.3
<i>Total</i>	330	100
All Clients		
Male	723	75.9
Female	230	24.1
<i>Total</i>	953	100

Table 28: Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	14	15.7	70	7.5
18-19	4	4.5	28	3.0
20-24	8	9.0	81	8.7
25-29	17	19.1	145	15.5
30-34	20	22.5	234	25.0
35-39	16	18.0	208	22.2
40-44	4	4.5	100	10.7
45+	6	6.7	69	7.4
Total	89	100	935	100

Table 29: Year to Date, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	47	14.2	88	9.2
18-19	14	4.2	30	3.1
20-24	40	12.1	100	10.5
25-29	61	18.5	203	21.3
30-34	70	21.2	251	26.3
35-39	48	14.5	165	17.3
40-44	34	10.3	70	7.3
45+	16	4.8	46	4.8
Total	330	100	953	100

Table 30: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	87	97.8	923	98.7
White Irish	0	0	3	0.3
Other White	1	1.1	1	0.1
White & Asian	0	0	1	0.1
Other Mixed	0	0	1	0.1
Indian	1	1.1	1	0.1
Other Black	0	0	1	0.1
Other	0	0	4	0.4
Total	89	100	935	100

Table 31: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	53	59.6	491	52.5
Methadone	6	6.7	90	9.6
Other Opiates	1	1.1	29	3.1
Benzodiazepine	0	0	8	0.9
Amphetamines	3	3.4	26	2.8
Cocaine	7	7.9	80	8.6
Crack	0	0	19	2.0
Ecstasy	2	2.3	15	1.6
Cannabis	15	16.9	166	17.8
Solvents	1	1.1	3	0.3
Other/Unknown	1	1.1	8	0.9
Total	89	100	935	100

COMBINED DATASETS

Quarter 4 (2006/07)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, Syringe Exchange (Agency and Pharmacy) and NDTMS. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 32: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	969	80.1
Female	240	19.9
Age Group		
Under 18	87	7.2
18-19	46	3.8
20-24	161	13.3
25-29	242	20.0
30-34	301	24.9
35-39	212	17.5
40-44	95	7.9
45+	65	5.4
Total	1209	100

Table 33: Year to Date, by Gender and Age Group

Age Group	Gender				Total in Age Group	
	Male		Female		n	%
	n	%	n	%		
Under 18	64	4.1	24	8.5	88	4.8
18-19	81	5.2	6	2.1	87	4.7
20-24	276	17.7	29	10.2	305	16.6
25-29	318	20.5	68	23.9	386	21.0
30-34	349	22.4	74	26.1	423	23.0
35-39	258	16.6	51	18.0	309	16.8
40-44	116	7.5	19	6.7	135	7.3
45+	93	6.0	13	4.6	106	5.8
Total	1555	100	284	100	1839	100

CROSS-MATCHED DATASETS

Quarter 4 (2006/07)

Data are shown for the crossover between each type of Syringe Exchange and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of Syringe Exchange site.

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets




Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

